Secondary pharmacology data to assess potential off-target activity of new drugs: a regulatory perspective-Reference-Cited by-同舟云学术

Secondary pharmacology data to assess potential off-target activity of new drugs: a regulatory perspective

Published:2015-03-20 Issue:4 Volume:14 Page:294-294
ISSN:1474-1776
Container-title:Nature Reviews Drug Discovery
language:en
Short-container-title:Nat Rev Drug Discov

Author:

Papoian Thomas,Chiu Haw-Jyh,Elayan Ikram,Jagadeesh Gowraganahalli,Khan Imran,Laniyonu Adebayo A.,Li Cindy Xinguang,Saulnier Muriel,Simpson Natalie,Yang Baichun

Publisher

Springer Science and Business Media LLC

Subject

Drug Discovery,Pharmacology,General Medicine

Link

http://www.nature.com/articles/nrd3845-c1.pdf

Reference10 articles.

1. Bowes, J. et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nature Rev. Drug Discov. 11, 909–922 (2012).

2. ICH Expert Working Group. Safety pharmacology studies for human pharmaceuticals S7A. ICH [online] , (2001).

3. Bass, A. S. et al. Exploratory drug safety: a discovery strategy to reduce attrition in development. J. Pharmacol. Toxicol. Methods 60, 69–78 (2009).

4. Hughes, J. P. et al. Principles of early drug discovery. Br. J. Pharmacol. 162, 1239–1249 (2011).

5. Lounkine, E. et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature 486, 361–367 (2012).

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endeavours made by trade associations, pharmaceutical companies and regulators in the replacement, reduction and refinement of animal experimentation in safety testing of pharmaceuticals;Regulatory Toxicology and Pharmacology;2024-09

2. Safety Implications of Modulating Nuclear Receptors: A Comprehensive Analysis from Non-Clinical and Clinical Perspectives;Pharmaceuticals;2024-07-03

3. Preclinical mitigation of 5-HT2B agonism-related cardiac valvulopathy revisited;Journal of Pharmacological and Toxicological Methods;2024-07

4. The state of the art in secondary pharmacology and its impact on the safety of new medicines;Nature Reviews Drug Discovery;2024-05-21

5. Developing a pragmatic consensus procedure supporting the ICH S1B(R1) weight of evidence carcinogenicity assessment;Frontiers in Toxicology;2024-04-05